Oral antirheumatic ‘Xeljanz’ settles the Big 4 hospitals in 9 months

Pfizer Pharmaceuticals Korea’s ‘Xeljanz(generic name: tofacitinib),’ an oral rheumatoid arthritis treatment, has been safely landed in the Big 4 hospitals within 9 months of the launch on March.

According to the medical industry on the 28^th, Severance Hospital, on the 28^th, unveiled pharmaceutical products which passed the therapeutics committee on December.

Among the products passing the Sev...